{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:33:14Z","timestamp":1789216394189,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.toxicon.2012.11.024","type":"journal-article","created":{"date-parts":[[2013,1,30]],"date-time":"2013-01-30T05:31:35Z","timestamp":1359523895000},"page":"81-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Clinical utility of different botulinum neurotoxin preparations"],"prefix":"10.1016","volume":"67","author":[{"given":"Steven B.","family":"Abrams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hallett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxicon.2012.11.024_bib1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF03033927","article-title":"Neurophysiological effects of botulinum toxin type A","volume":"9","author":"Abbruzzese","year":"2006","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.toxicon.2012.11.024_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001408","article-title":"Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy","author":"Ade-Hall","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.toxicon.2012.11.024_bib3","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2215\/CJN.02850806","article-title":"A primer on the design, conduct, and interpretation of clinical trials","volume":"1","author":"Appel","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.toxicon.2012.11.024_bib4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.pbb.2009.08.012","article-title":"Central origin of the antinociceptive action of botulinum toxin type A","volume":"94","author":"Bach-Rojecky","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.toxicon.2012.11.024_bib5","series-title":"Botox [Package Insert]","year":"2010"},{"key":"10.1016\/j.toxicon.2012.11.024_bib6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/jnnp.52.3.355","article-title":"Treatment of focal dystonias of the hand with botulinum toxin injections","volume":"52","author":"Cohen","year":"1989","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2012.11.024_bib7","article-title":"Botulinum toxin type A versus botulinum toxin type B for cervical dystonia","author":"Costa","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.toxicon.2012.11.024_bib8","article-title":"Botulinum toxin type A therapy for blepharospasm","author":"Costa","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.toxicon.2012.11.024_bib9","article-title":"Botulinum toxin type A therapy for hemifacial spasm","author":"Costa","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.toxicon.2012.11.024_bib10","article-title":"Botulinum toxin type B for cervical dystonia","author":"Costa","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.toxicon.2012.11.024_bib11","article-title":"Botulinum toxin type A versus anticholinergics for cervical dystonia","author":"Costa","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.toxicon.2012.11.024_bib12","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/j.1526-4610.2011.02022.x","article-title":"Insights into the mechanism of onabotulinumtoxinA in chronic migraine","volume":"51","author":"Durham","year":"2011","journal-title":"Headache"},{"key":"10.1016\/j.toxicon.2012.11.024_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005493.pub2","article-title":"Botulinum toxin injections for adults with overactive bladder syndrome","author":"Duthie","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.toxicon.2012.11.024_bib14","series-title":"Dysport [Package Insert]","year":"2009"},{"key":"10.1016\/j.toxicon.2012.11.024_bib15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00702-007-0728-2","article-title":"From poison to remedy: the chequered history of botulinum toxin","volume":"115","author":"Erbguth","year":"2008","journal-title":"J. Neural Transm."},{"issue":"Suppl. 2","key":"10.1016\/j.toxicon.2012.11.024_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1331.2010.03125.x","article-title":"International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments \u2013 introduction","volume":"17","author":"Esquenazi","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2012.11.024_bib17","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.pain.2010.07.029","article-title":"Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis","volume":"151","author":"Gazerani","year":"2010","journal-title":"Pain"},{"key":"10.1016\/j.toxicon.2012.11.024_bib18","first-page":"27","article-title":"Neurotoxin therapy: a closer look at the four options","volume":"9","author":"Gollomp","year":"2011","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.toxicon.2012.11.024_bib19","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1001\/jama.2009.1756","article-title":"The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses","volume":"302","author":"Hennekens","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.toxicon.2012.11.024_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003469.pub4","article-title":"Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE)","author":"Hoare","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.toxicon.2012.11.024_bib21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2007.10.013","article-title":"Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity\/neurogenic overactive bladder: a systematic literature review","volume":"53","author":"Karsenty","year":"2008","journal-title":"Eur. Urol."},{"key":"10.1016\/j.toxicon.2012.11.024_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuroscience.2011.04.026","article-title":"Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A","volume":"186","author":"Matak","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.toxicon.2012.11.024_bib23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.biochem.051908.125345","article-title":"Botulinum neurotoxin: a marvel of protein design","volume":"79","author":"Montal","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.toxicon.2012.11.024_bib24","series-title":"Myobloc [Package Insert]","year":"2010"},{"key":"10.1016\/j.toxicon.2012.11.024_bib25","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1212\/01.wnl.0000311390.87642.d8","article-title":"Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"70","author":"Naumann","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2012.11.024_bib26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1478-4505-4-28","article-title":"Improving the use of research evidence in guideline development: 16","volume":"4","author":"Oxman","year":"2006","journal-title":"Evaluation. Health Res. Policy Syst."},{"key":"10.1016\/j.toxicon.2012.11.024_bib27","article-title":"More women try the Botox way to stay young: over one million treatments carried out each year for the first time","author":"Poulter","year":"2011","journal-title":"The Daily\u00a0Mail"},{"key":"10.1016\/j.toxicon.2012.11.024_bib28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/MMBR.56.1.80-99.1992","article-title":"Properties and use of botulinum toxin and other microbial neurotoxins in medicine","volume":"56","author":"Schantz","year":"1992","journal-title":"Microbiol. Rev."},{"key":"10.1016\/j.toxicon.2012.11.024_bib29","first-page":"734","article-title":"Botulinum toxin injection of eye muscles to correct strabismus","volume":"79","author":"Scott","year":"1981","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"10.1016\/j.toxicon.2012.11.024_bib30","first-page":"924","article-title":"Pharmacologic weakening of extraocular muscles","volume":"12","author":"Scott","year":"1973","journal-title":"Invest. Ophthalmol."},{"key":"10.1016\/j.toxicon.2012.11.024_bib31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7326\/0003-4819-147-4-200708210-00179","article-title":"How quickly do systematic reviews go out of date? A survival analysis","volume":"147","author":"Shojania","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.toxicon.2012.11.024_bib32","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","article-title":"Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2012.11.024_bib33","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1212\/01.wnl.0000311391.00944.c4","article-title":"Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2012.11.024_bib34","author":"Singer"},{"key":"10.1016\/j.toxicon.2012.11.024_bib35","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/78005","article-title":"Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B","volume":"7","author":"Swaminathan","year":"2000","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.toxicon.2012.11.024_bib36","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/16501970306112","article-title":"Use of botulinum toxin type A in management of adult spasticity \u2013 a European consensus statement","volume":"35","author":"Ward","year":"2003","journal-title":"J. Rehabil. Med."},{"key":"10.1016\/j.toxicon.2012.11.024_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003469.pub3","article-title":"Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy","volume":"3","author":"Wasiak","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.toxicon.2012.11.024_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003469.pub3","article-title":"Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy","volume":"4","author":"Wasiak","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.toxicon.2012.11.024_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004327.pub2","article-title":"Botulinum toxin injections for the treatment of spasmodic dysphonia","author":"Watts","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.toxicon.2012.11.024_bib40","series-title":"Xeomin [Package Insert]","year":"2011"}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010112008197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010112008197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T07:45:15Z","timestamp":1595317515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010112008197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":40,"alternative-id":["S0041010112008197"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2012.11.024","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical utility of different botulinum neurotoxin preparations","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2012.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}